Trans-Hit Biomarkers - Prospective Biobanking Services

By: Trans-hit Biomarkers  09-12-2011

When conducting clinical research for eventual submission to the FDA, great care must be taken to utilize the most appropriate samples. Both prospective and retrospective samples can be used, but each has its own set of drawbacks and regulatory concerns. Trans-Hit Biomarkers can help you decide which path is right for your clinical and regulatory plans, as well as help you to find retrospective samples to fit your needs.

Trans-Hit Biomarkers will take care of the selection, set-up and monitoring of investigator sites when multicenter prospective studies are needed for the clinical validation of new biomarkers, maintaining high-quality standards for biospecimen sampling, shipping and storage.

Having access to a database of more than 1,500 biobanks all over the world, Trans-Hit Biomarkers has the tools to locate and select the best investigators sites for any specific disease.

For large international studies, Trans-Hit Biomarkers has established a preferred provider relationship with Covance Inc.




Designed to target specific clinical / therapeutical needs

Long time to collect

Collects all required clinical data

Time consuming legal/regulatory hurdles

Addresses intended use


Collection readily available May or may not have all required patient data available
Samples targeted at the therapeutic area in general Informed consent may be restrictive, or if no informed consent is available: must need the FDA/legal requirements for use as left-over specimens

Less expensive

Addresses the intended use

The use of retrospective samples is not the right solution in every single case. However, depending upon the classification of your product within the regulatory guidelines and your intended use application, retrospective samples could potentially save you significant time and money.

Let Trans-Hit Biomakers help you determine the best path forward for your specimen, clinical and regulatory needs.

Regardless of the type of biospecimen you collect, the requirements for compliance with the regulations of the US and the rest of world are well-defined. Trans-Hit Biomarkers can assist you in defining and establishing these needs and in executing your trials. Through strategic partnerships Trans-Hit Biomarkers can assist you with all your needs, assuring total compliance and seamless integration through to completion, including all of the following:

  • Clinical protocol (ICH & GCP requirements)
  • IRB / IEC approvals
  • Site and investigator selection
  • Clinical monitoring
  • Biospecimen collection and storage logistics
  • Data management

Contact Trans-hit Biomarkers

Email - none provided

Print this page

Other products and services from Trans-hit Biomarkers


Trans-Hit Biomarkers - Unique services to TTOs and their scientists developing new biomarkers and diagnostic technologies

Our expertise in helping biomarker scientists to advance their biomarkers to the market is widely recognized by many well-known TTOs and key industrial players in the biomarker domain. At Trans-Hit Biomarkers we know the challenges you face in taking your newly discovered biomarker through validation and eventually to a commercialized product.


Trans-Hit Biomarkers - Regulatory Services

Based on the regulatory path that we will define for you, we can help you optimize each step of your research and development plan from concept to marketing strategy. Our corporate goal is to develop long-term relationships and commitments with our clients and to provide high-quality, comprehensive services and expert support.


Trans-Hit Biomarkers - Access To Animal Models

In addition, selected preclinical CRO partners have extensive knowledge and expertise in their respective fields of specialization, offering Trans-Hit Biomarkers and its clients the ability to evaluate the pertinence of their biomarkers.


Trans-Hit Biomarkers - Proteome-Hit

By combining Trans-hit Biomarkers’ access to large high-quality biospecimen collections with Caprion’s high-throughput and quantitative multiplexed mass spectrometry assays, Proteome-Hit turns the usually expensive and time-consuming clinical validation route into a fast, cost-effective and robust process.


Trans-Hit Biomarkers - Access To Human Biospecimen Collections

Assuming sample collections are of good quality and that the scientific, legal and regulatory challenges have been overcome, sample-based research should ultimately lead to the discovery and validation of new biomarkers for predictive, prognostic, surrogate and efficacy diagnostic tests.


Trans-Hit Biomarkers - ImaProteome

MALDI-Imaging Mass Spectrometry technology developed by ImaBiotech allows to generate molecular images and to quantify the distribution of molecules in complex samples such as organs, tissues and biopsies, without labeling, extraction/purification and degradation. Via automation and data processing, molecular maps of molecules can be easily generated from tissue sections collected from patients with cancer, CNS diseases, and many other diseases.